Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria

Oche Agbaji; Chloe L. Thio; Seema Meloni; Camilla Graham; Mohammed Muazu; Ladep Nimzing; John Idoko; Jean Louis Sankalé; Ernest Ekong; Robert Murphy; Phyllis Kanki; Claudia Hawkins

doi:10.1097/QAI.0b013e31827ce536

Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria

Oche Agbaji, Chloe L. Thio, Seema Meloni, Camilla Graham, Mohammed Muazu, Ladep Nimzing, John Idoko, Jean Louis Sankalé, Ernest Ekong, Robert Murphy, Phyllis Kanki, Claudia Hawkins

School of Medicine

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.

Original language	English (US)
Pages (from-to)	204-207
Number of pages	4
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	62
Issue number	2
DOIs	https://doi.org/10.1097/QAI.0b013e31827ce536
State	Published - Feb 1 2013

Keywords

Africa
HIV
antiretroviral therapy
hepatitis C

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

Access to Document

10.1097/QAI.0b013e31827ce536

Cite this

@article{e545de27ad3a4adcb44390baa9e9a0b4,

title = "Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria",

abstract = "The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.",

keywords = "Africa, HIV, antiretroviral therapy, hepatitis C",

author = "Oche Agbaji and Thio, {Chloe L.} and Seema Meloni and Camilla Graham and Mohammed Muazu and Ladep Nimzing and John Idoko and Sankal{\'e}, {Jean Louis} and Ernest Ekong and Robert Murphy and Phyllis Kanki and Claudia Hawkins",

year = "2013",

month = feb,

day = "1",

doi = "10.1097/QAI.0b013e31827ce536",

language = "English (US)",

volume = "62",

pages = "204--207",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria

AU - Agbaji, Oche

AU - Thio, Chloe L.

AU - Meloni, Seema

AU - Graham, Camilla

AU - Muazu, Mohammed

AU - Nimzing, Ladep

AU - Idoko, John

AU - Sankalé, Jean Louis

AU - Ekong, Ernest

AU - Murphy, Robert

AU - Kanki, Phyllis

AU - Hawkins, Claudia

PY - 2013/2/1

Y1 - 2013/2/1

N2 - The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.

AB - The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.

KW - Africa

KW - HIV

KW - antiretroviral therapy

KW - hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=84872854079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872854079&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31827ce536

DO - 10.1097/QAI.0b013e31827ce536

M3 - Article

C2 - 23196830

AN - SCOPUS:84872854079

SN - 1525-4135

VL - 62

SP - 204

EP - 207

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 2

ER -

Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this